Literature DB >> 12543084

Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.

Hakan Akbulut1, Fevzi Altuntas, K Gonca Akbulut, Guler Ozturk, Mehmet Cindoruk, Ekrem Unal, Fikri Icli.   

Abstract

Recently, angiogenesis has gained an increasing interest as a prognostic factor in a variety of solid tumours. In this study we aimed to assess the prognostic role of serum vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b-FGF) and nitric oxide (NO) levels in patients with colorectal carcinoma (CRC).A total of 52 consecutive colorectal cancer patients with stage I to IV disease was included. In addition to routine laboratory and staging procedures, serum VEGF, b-FGF levels, and nitrate levels as a surrogate marker for in-vivo NO production were assayed. Serum VEGF concentrations, adjusted to the platelet count were found to be a significant factor for overall survival in univariate analysis (P=0.033). A new angiogenic index (AI), derived from serum VEGF and nitrate concentrations, was established. AI is the only independent prognostic factor of survival in all patients (P=0.008, Cox regression analysis). Likewise, AI is also significant prognostic factor for disease-free survival (DFS) in patients with operable CRC (P=0.032, Cox regression analysis). In conclusion, serum VEGF and NO levels have prognostic role in patients with CRC and the new angiogenesis index using the serum levels of the factors seem to be useful.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12543084     DOI: 10.1006/cyto.2002.1993

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  16 in total

1.  Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer.

Authors:  Yitao Jia; Min Liu; Wangang Huang; Zhenbao Wang; Yutong He; Jianhua Wu; Shuguang Ren; Yingchao Ju; Ruichao Geng; Zhongxin Li
Journal:  Pathol Oncol Res       Date:  2011-09-22       Impact factor: 3.201

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 3.  The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Semin Oncol       Date:  2006-12       Impact factor: 4.929

Review 4.  Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients.

Authors:  Matteo Donadon; Nina Cortese; Federica Marchesi; Matteo Cimino; Alberto Mantovani; Guido Torzilli
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

Review 5.  Hyperbaric oxygen therapy for malignancy: a review.

Authors:  Jurstine Daruwalla; Chris Christophi
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

6.  Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

Review 7.  Vascular endothelial growth factor in colorectal cancer.

Authors:  Markus Guba; Hendrik Seeliger; Axel Kleespies; Karl-Walter Jauch; Christiane Bruns
Journal:  Int J Colorectal Dis       Date:  2004-03-04       Impact factor: 2.571

8.  Serum vascular endothelial growth factor and angiogenesis are related to the prognosis of patients with gastrointestinal stromal tumors.

Authors:  T B Wang; W S Qiu; B Wei; M H Deng; H B Wei; W G Dong
Journal:  Ir J Med Sci       Date:  2009-04-15       Impact factor: 1.568

9.  Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.

Authors:  Mevlüde Inanç; Ozlem Er; Halit Karaca; Veli Berk; Metin Ozkan; Recep Saraymen; Ferhan Elmalı
Journal:  Med Oncol       Date:  2012-05-12       Impact factor: 3.064

10.  XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.

Authors:  Dimitrios Pectasides; George Papaxoinis; Konstantine T Kalogeras; Anastasia G Eleftheraki; Ioannis Xanthakis; Thomas Makatsoris; Epaminondas Samantas; Ioannis Varthalitis; Pavlos Papakostas; Nikitas Nikitas; Christos N Papandreou; George Pentheroudakis; Eleni Timotheadou; Angelos Koutras; Joseph Sgouros; Dimitrios Bafaloukos; George Klouvas; Theofanis Economopoulos; Konstantinos N Syrigos; George Fountzilas
Journal:  BMC Cancer       Date:  2012-06-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.